February 22, 2008西北职教
New Anticoagulants for Treatment of Venous Thromboembolism
Key result
Emerging anticoagulants, including idraparinux and new oral agents targeting thrombin or factor Xa, have the potential to streamline the treatment of venous thromboembolism.
Why the study?
Do emerging anticoagulants (idraparinux and new oral anticoagulants) improve the treatment and management of venous thromboembolism compared to standard therapy?
Population
Patients with venous thromboembolism (VTE)
Comparison
Emerging anticoagulants including idraparinux… vs Standard anticoagulant therapy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Prognostic data on VTE anticoagulation stages remain limited; leaves open optimal duration and agent choice in contemporary practice.
Structured PICO
Do emerging anticoagulants (idraparinux and new oral anticoagulants) improve the treatment and management of venous thromboembolism compared to standard therapy?
P
Population
Patients with venous thromboembolism (VTE)
I
Intervention
Emerging anticoagulants including idraparinux (once-weekly subcutaneous) and new oral anticoagulants targeting thrombin or factor Xa
C
Comparator
Standard anticoagulant therapy (parenteral agents such as heparin, low-molecular-weight heparin, or fondaparinux, and vitamin K antagonists such as warfarin)
This review outlines the pharmacology, clinical trial results, and evolving role of emerging anticoagulants like idraparinux and direct oral anticoagulants for VTE treatment.
Cite This Study
Gross et al. (2008) conducted a review in Venous thromboembolism. New anticoagulants (idraparinux, oral thrombin or factor Xa inhibitors) was evaluated. Emerging anticoagulants, including idraparinux and new oral agents targeting thrombin or factor Xa, have the potential to streamline the treatment of venous thromboembolism.